Antimüllerian hormone levels are strongly associated with live-birth rates after assisted reproduction

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 3, 2013, Pages 1107-1114

  Brodin, Thomas ^a,b   Hadziosmanovic, Nermin ^c   Berglund, Lars ^c   Olovsson, Matts ^a   Holte, Jan ^a,b,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b Carl von Linne Kliniken   (Sweden)

^c UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^d Swedish University of Agricultural Sciences   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; HUMAN MENOPAUSAL GONADOTROPIN; MUELLERIAN INHIBITING FACTOR; NAFARELIN; RECOMBINANT FOLLITROPIN;

ADULT; AGE DISTRIBUTION; BIRTH RATE; COHORT ANALYSIS; CONTROLLED STUDY; EMBRYO QUALITY; EMBRYO TRANSFER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMALE GENITAL TRACT PARAMETERS; FERTILIZATION IN VITRO; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; INFERTILITY; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; MAJOR CLINICAL STUDY; OOCYTE QUALITY; OOCYTE YIELD; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME;

ADULT; ANTI-MULLERIAN HORMONE; FEMALE; FERTILIZATION IN VITRO; HUMANS; INFERTILITY, FEMALE; MULTIVARIATE ANALYSIS; OOCYTES; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; PROGNOSIS; PROSPECTIVE STUDIES; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 84874850952     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3676     Document Type: Review

References (38)

1. te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update. 2002;8:141-154. (Pubitemid 34428965)
2. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685-718. (Pubitemid 44605509)
3. Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A. Anti-Müllerian hormone: clairvoyance or crystal clear? Hum Reprod. 2012;27:631-636.
4. Holte J, Brodin T, Berglund L, Hadziosmanovic N, Olovsson M, Bergh T. Antral follicle counts are strongly associated with live-birth rates after assisted reproduction, with superior treatment outcome in women with polycystic ovaries. Fertil Steril. 2011;96:594-599.
5. Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology. 1999;140:5789-5796. (Pubitemid 30645368)
6. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77-83. (Pubitemid 38196508)
7. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Müllerian hormone throughout the human menstrual cycle. Hum Reprod. 2006;21:3103-3107. (Pubitemid 44811610)
8. van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BC, Broekmans FJ. Comparison of inter-and intra-cycle variability of anti-Müllerian hormone and antral follicle counts. Hum Reprod. 2010;25:221-227.
9. Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti-Müllerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod. 2005;20:923-927. (Pubitemid 40667836)
10. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16:113-130.
11. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82:1323-1329. (Pubitemid 39469455)
12. Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod. 2007;22:2414-2421. (Pubitemid 47289055)
13. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, Ambrose P, Fleming R. Anti-Müllerian hormonebased approach to controlled ovarian stimulation for assisted conception. Hum Reprod. 2009;24:867-875.
14. Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS. Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrinol. 2009;7:100.
15. La Marca A, Nelson SM, Sighinolfi G, Manno M, Baraldi E, Roli L, Xella S, Marsella T, Tagliasacchi D, D'Amico R, Volpe A. Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction. Reprod Biomed Online. 2011;22:341-349.
16. Webber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K, Franks S. Formation and early development of follicles in the polycystic ovary. Lancet. 2003;362:1017-1021. (Pubitemid 37186878)
17. Stubbs SA, Hardy K, Da Silva-Buttkus P, Stark J, Webber LJ, Flanagan AM, Themmen AP, Visser JA, Groome NP, Franks S. Antimu ̈llerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. J Clin Endocrinol Metab. 2005;90:5536-5543. (Pubitemid 41415455)
18. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D. Elevated serum level of anti-müllerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88:5957-5962. (Pubitemid 38033078)
19. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A, Catteau-Jonard S. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26:3123-3129.
20. Brodin T, Bergh T, Berglund L, Hadziosmanovic N, Holte J. Menstrual cycle length is an age-independent marker of female fertility: results from 6271 treatment cycles of in vitro fertilization. Fertil Steril. 2008;90:1656-1661.
21. Brodin T, Bergh T, Berglund L, Hadziosmanovic N, Holte J. High basal LH levels in combination with low basal FSH levels are associated with high success rates at assisted reproduction. Hum Reprod. 2009;24:2755-2759.
22. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9:505-514. (Pubitemid 38072143)
23. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 19:41-47.
24. Holte J, Berglund L, Milton K, Garello C, Gennarelli G, Revelli A, Bergh T. Construction of an evidence-based integrated morphology cleavage embryo score for implantation potential of embryos scored and transferred on day 2 after oocyte retrieval. Hum Reprod. 2007;22:548-557. (Pubitemid 46152580)
25. Holte J, Berglund L, Hadziosmanovic N, Tilly J, Pettersson H, Bergh T. The construction and validation of a prediction model to minimize twin rates at preserved live birth rates in ART. Paper presented at 27th Annual Meeting of the European Society of Human Reproduction & Embryology (ESHRE); July 2011; Stockholm, Sweden.
26. de Boer EJ, den Tonkelaar I, te Velde ER, Burger CW, van Leeuwen FE, OMEGA-Project Group. Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment. Hum Reprod. 2003;18:1544-1552. (Pubitemid 36840968)
27. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
28. Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, Keefe DL, Blazar AS. Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum Reprod. 2006;21:159-163. (Pubitemid 41794305)
29. Simón C, Cano F, Valbuena D, Remohí J, Pellicer A. Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients. Hum Reprod. 1995;10:2432-2437.
30. Santos MA, Kuijk EW, Macklon NS. The impact of ovarian stimulation for IVF on the developing embryo. Reproduction. 2010;139:23-34.
31. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005;20:1820-1826. (Pubitemid 40932362)
32. Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, Ehrmann DA. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012;98:242-249.
33. Nikolaou D, Gilling-Smith C. Early ovarian ageing: are women with polycystic ovaries protected? Hum Reprod. 2004;19:2175-2179. (Pubitemid 39406672)
34. Hudecova M, Holte J, Olovsson M, Sundström Poromaa I. Longterm follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve. Hum Reprod. 2009;24:1176-1183.
35. Laven JS, Mulders AG, Visser JA, Themmen AP, DeJong FH, Fauser BC. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89:318-323. (Pubitemid 38183899)
36. Dewailly D, Pigny P, Soudan B, Catteau-Jonard S, Decanter C, Poncelet E, Duhamel A. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab. 2010;95:4399-4405.
37. Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman S, Baird DD. Antimüllerian hormone as a predictor of natural fecundability in women aged 30-42 years. Obstet Gynecol. 2011;117:798-804.
38. Verberg MF, Eijkemans MJ, Macklon NS, Heijnen EM, Baart EB, Hohmann FP, Fauser BC, Broekmans FJ. The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis. Hum Reprod Update. 2009;15:5-12.